What's new
  • Happy Birthday ICMag! Been 20 years since Gypsy Nirvana created the forum! We are celebrating with a 4/20 Giveaway and by launching a new Patreon tier called "420club". You can read more here.
  • Important notice: ICMag's T.O.U. has been updated. Please review it here. For your convenience, it is also available in the main forum menu, under 'Quick Links"!

:::::::Indiana Cannabis Reform Legislation::::::

pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
I can't remember if I mentioned earlier, a friend of mine told me a couple years ago he goes to the Bahamas to get Iboga therapy! It helps repair his mind he said.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
SB 139Psilocybin treatment program.Charbonneau, Johnson T
SB 139 is being presented on the Senate floor this afternoon!

Senate Calendar​

Feb 5, 2024 (Version 1)
Open as PDF
President Pro Tempore Rodric BrayMeeting Day:Monday, Feb 5, 2024
IGA Logo

State of Indiana123rd General Assembly
Principal Secretary Jennifer MertzConvening Time:1:30 PM
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran

Also up on the floor today. Currency regulation and monetary policy affects the cannabis industry.​

​

Senate Bill 180​

Central bank digital currency.​

Senate Bill (S)​

Authored by:
Sen. Eric Koch, Sen. Mark Messmer.
Co-Authored by:
Sen. Mike Gaskill.

Digest​

Prohibits a governmental body (defined as the state or a state agency) from: (1) accepting payment made with a central bank digital currency; or (2) requiring payment to be made with a central bank digital currency; for any service, tax, license, permit, fee, information, or other amount due the governmental body. Prohibits an administrative branch governmental body (defined as an entity of the administrative branch of state government) from advocating for or supporting the testing, adoption, or implementation of a central bank digital currency by the United States government. Defines "central bank digital currency" for purposes of these provisions.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
Senator Taylor introduces amendmet to SB 139 for Medicinal CAnnabis

Senate may FORCE a VOTE on IT

ARTICLE 8. MEDICAL MARIJUANA
32 Chapter 1. Definitions
33 Sec. 1. The following definitions apply throughout this article:
34 (1) "Adequate supply for treatment" means the amount of
35 marijuana necessary to provide care for a treatable medical
36 condition for a thirty (30) day period, as determined by a
37 physician recommendation.
38 (2) "Marijuana" means any part of the plant genus Cannabis.
39 (3) "Medical marijuana card" means a valid card issued by
40 the regulatory agency that authorizes the individual to whom
41 the card is issued to possess marijuana.
42 (4) "Physician" means an individual holding an unlimited
43 license to practice medicine in Indiana.
44 (5) "Physician recommendation" means a written
45 recommendation that the use of marijuana may benefit a
46 particular patient suffering from a treatable medical
MO013901/DI 106 2024
6
1 condition. A physician recommendation may specify an
2 adequate supply for treatment.
3 (6) "Qualified patient" means an individual who has been
4 issued a medical marijuana card by the regulatory agency.
5 (7) "Qualified primary caregiver" means the primary
6 caregiver for a qualified patient who has been issued a
7 medical marijuana card by the regulatory agency on behalf of
8 the qualified patient.
9 (8) "Regulatory agency" means the regulatory agency
10 established by IC 7.1-9-2-1.
11 (9) "Regulatory agency commission" means the regulatory
12 agency commissioners described in IC 7.1-9-2.
13 (10) "Treatable medical condition" means an illness or other
14 condition, the symptoms of which (including the side effects
15 and symptoms caused by any other treatment for the
16 condition) may be treated by the use of marijuana. The term
17 includes the following:
18 (A) Acquired immune deficiency syndrome (AIDS) or
19 positive status for the human immunodeficiency virus
20 (HIV).
21 (B) Anorexia.
22 (C) Arthritis.
23 (D) Cachexia.
24 (E) Chronic cancer pain.
25 (F) Glaucoma.
26 (G) Migraine.
27 (H) Persistent muscle spasms, including spasms associated
28 with multiple sclerosis, Crohn's disease, or related
29 conditions.
30 (I) Seizures, including those characteristic of epilepsy.
31 (J) Severe nausea.
32 (K) Posttraumatic stress disorder.
33 (L) Any persistent or chronic illness or condition that, in
34 the opinion of a physician:
35 (i) substantially limits the ability of an individual to
36 conduct one (1) or more major life activities; or
37 (ii) may cause serious harm to a patient's safety or
38 mental or physical health if not alleviated;
39 if the illness or condition may be improved by the use of
40 marijuana.
41 (M) Any other illness or condition determined by the
42 regulatory agency to be a treatable medical condition.
43 Chapter 2. Qualified Patients and Qualified Primary Caregivers
44 Sec. 1. (a) An individual may apply to the regulatory agency to
45 be a qualified patient if the individual suffers from a treatable
46 medical condition. An individual may apply to the regulatory
47 agency to be a qualified primary caregiver if the individual for
MO013901/DI 106 2024
7
1 whom the individual provides care suffers from a treatable medical
2 condition.
3 (b) To be approved as a qualified patient, an individual must
4 submit to the regulatory agency a physician recommendation
5 stating that the individual suffers from a treatable medical
6 condition. To be approved as a qualified primary caregiver, an
7 individual must submit to the regulatory agency a physician
8 recommendation stating that the individual for whom the caregiver
9 provides care suffers from a treatable medical condition.
10 (c) The regulatory agency shall issue to an individual a medical
11 marijuana card indicating that the individual is a qualified patient
12 or a qualified primary caregiver after:
13 (1) receipt of a:
14 (A) completed application; and
15 (B) physician recommendation;
16 (2) verification that the individual who tendered the physician
17 recommendation is a licensed physician; and
18 (3) compliance with any other rule adopted by the regulatory
19 agency.
20 (d) An application for a medical marijuana card may be denied
21 for the following reasons:
22 (1) The application is not complete or required information is
23 missing.
24 (2) The applicant submits false information.
25 (3) The applicant does not meet the criteria required to obtain
26 a medical marijuana card.
27 (4) The individual who tendered the physician
28 recommendation is not a licensed physician.
29 (e) A medical marijuana card issued under this section is valid
30 for two (2) years, unless the physician recommendation expressly
31 recommends a shorter period.
32 (f) The regulatory agency may charge a reasonable fee, not to
33 exceed one hundred dollars ($100), to apply for a medical
34 marijuana card. The fee shall be deposited in the state general
35 fund.
36 (g) Except as provided in subsection (h), for purposes of
37 IC 5-14-3-4(a)(1), the following information is confidential, may
38 not be published, and is not open to public inspection:
39 (1) Information submitted by an individual under this section
40 to obtain a medical marijuana card.
41 (2) Information obtained by a federal, state, or local
42 government entity in the course of an investigation concerning
43 an individual who applies to obtain a medical marijuana card.
44 (3) The name and address of the individual, and any other
45 information that may be used to identify an individual, who
46 holds a medical marijuana card.
47 (h) Notwithstanding subsection (g):
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
Taylor has since withdrawn motion to amendment #1 SB 139

He was made a point in support of bringing the topic of medicinal cannabis to the floor of the legislature, and voiced his concern that there hasn't been any hearings on cannabis.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
Taylor cited the recent Ball State University survey which found 85% support for Cannabis reform for either medical or adult-use, and 10% support for prohibition.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
Senator Taylor took a stand, it was great. He said, just as the author of the bill has said, this bill doesn't legalize anything that's not already legal.

None of the legislators questioned the amendment or spoke up, so the amendment as withdrawn. Taylor said he would withdraw the amendment so it doesn't hold up a good bill SB 139.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran

Indiana General Assembly

Website for Indiana's General Assembly
iga.in.gov iga.in.gov

SB 139 Psilocybin Treatment Program passed the Senate and will now go to the House of Representatives to be presented.

Bill passed without Amendment #1 Medical cannabis program.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
www.marijuanamoment.net

Indiana Senate Passes GOP-Led Psilocybin Research Bill, With Democrats Filing But Not Forcing Vote On Medical Marijuana Amendment

The Indiana Senate on Tuesday overwhelmingly passed a Republican-led bill that would fund clinical research trials into psilocybin. The top Democratic senator filed an amendment that would have added language to the legislation to create a medical cannabis program in the state, though he did not...
www.marijuanamoment.net www.marijuanamoment.net

Indiana Senate Passes GOP-Led Psilocybin Research Bill, With Democrats Filing But Not Forcing Vote On Medical Marijuana Amendment​


Published
4 hours ago
on
February 6, 2024

By
Tom Angell

The Indiana Senate on Tuesday overwhelmingly passed a Republican-led bill that would fund clinical research trials into psilocybin. The top Democratic senator filed an amendment that would have added language to the legislation to create a medical cannabis program in the state, though he did not force a vote on it.


The Senate advanced the psychedelics measure to the House in a 47-1 vote. The action follows the proposal being passed unanimously by the Senate Appropriations Committee last week and the Health and Provider Services Committee last month.


“This bill provides hope to many individuals that are today in a hopeless situation,” Sen. Ed Charbonneau (R), the bill’s sponsor, said ahead of the floor vote. “I hope you feel the same and will vote for this bill.”



Sen. Greg Taylor (D), the minority leader, also rose in support of the measure, saying it is “a very, very important piece of legislation.”


“I want to thank Sen. Charbonneau for taking the great leap of faith to get this out there,” he said. “This could provide some really significant relief to a lot of Hoosiers here in the state of Indiana.”



Ahead of the floor session, Taylor had filed a 24-page amendment that would have inserted provisions into the bill to create a medical marijuana program in Indiana. Patients with cancer, multiple sclerosis, PTSD and other conditions would have been able to get doctors recommendations allowing them to legally possess eight ounces of cannabis and grow up to 12 marijuana plants at home.


The top Democrat did not force a vote on his amendment, however, nor did he mention it in his brief remarks ahead of the vote on the psilocybin bill, which now heads to the House of Representatives for consideration.



If the psychedelics measure becomes law, the measure would create a therapeutic psilocybin research fund “for the purpose of providing financial assistance to research institutions in Indiana to study…the use of psilocybin to treat mental health and other medical conditions.” Any research receiving funding under the bill would need to include veterans and first responders regarding in the study sample.


Researchers would need to apply to the state Department of Health to receive funds to study the substance as a treatment for conditions, six of which are specified in the bill: PTSD “with a focus on treating the disorder in combat veterans and first responders,” anxiety, depression, bipolar disorder, chronic pain and migraines.


The studies would need to “compare the efficacy of psilocybin as a treatment for mental health and other medical conditions…with the efficacy of other current treatment options.”



The bill would become effective immediately upon passage, as it was filed as an emergency measure. Officials would need to establish a process to administer the fund and process applications by July 1.

At the bill’s first committee stop this year, former Indiana State Health Commissioner Richard Feldman said that using psychedelics to treat behavioral disorders “may sound like a pretty crazy thing to do on first consideration. That’s what I thought when I first heard about this.”



“But recent studies have shown impressive results conducted by respected institutions, and reported in mainstream publications,” he added. “Examples include the New England Journal of Medicine, the Journal of Psychopharmacology and the Journal of American Medical Association. Authoring institutions include Harvard, Hopkins, and New York University among others. This is in no way fringe science.”


A state-created study committee recently recommended that lawmakers authorize a psilocybin pilot program to research psychedelic-assisted therapy for mental health during this year’s legislative session, advising that “the Indiana General Assembly take an approach that strikes a balance between access, research, and prudence.”



While psilocybin is classified as a Schedule I controlled substance at the federal level, the body said, the “prevailing view is that psilocybin should not be a Schedule I drug and has proven medical benefits.”


Charbonneau said late last year that he was already in touch with people at Indiana University Health and Purdue University about psychedelic research.


“I have had discussions with both IU Health and with Purdue University,” he said. “I spoke to 150 pharmacy students at Purdue, and afterward had a chance to speak with the dean of the pharmacy program…and he texted Dr. Jerome Adams, who’s now at Purdue University.”


Adams, a former U.S. surgeon general under then-President Donald Trump, joined Purdue in October 2021. While he’s said little publicly about psychedelic-assisted therapy, he’s previously claimed that “there’s no such thing as medical marijuana.”



Indiana lawmakers have been considering marijuana legalization but so far have yet to take concrete steps toward the reform in the GOP-controlled legislature. Another interim study group heard testimony around the possibility of decriminalizing simple cannabis possession in November, but the group did not make any specific recommendations.


In an op-ed for Marijuana Moment, Rep. Blake Johnson (D) wrote recently that Indiana is “falling far behind” on marijuana as its neighboring states legalize. “I implore my fellow legislators to listen to the statistics. It’s time for Indiana to sow the seeds and reap the economic benefits of cannabis,” he wrote.



One supportive lawmaker—Rep. Justin Moed (D)—managed to force a vote on marijuana legalization in the House last year, but Republicans rejected the proposal.
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
You must log in or register to reply here.

Latest posts

Latest posts

Top